ValuEngine upgraded shares of Intec Pharma (NASDAQ:NTEC) from a hold rating to a buy rating in a report released on Monday, February 4th.
A number of other equities analysts also recently commented on NTEC. LADENBURG THALM/SH SH reiterated a buy rating and set a $12.00 price objective on shares of Intec Pharma in a research report on Tuesday, January 29th. Zacks Investment Research downgraded Intec Pharma from a buy rating to a hold rating in a research report on Wednesday, November 21st. HC Wainwright reiterated a buy rating and set a $16.00 price objective on shares of Intec Pharma in a research report on Monday, December 10th. Finally, BidaskClub downgraded Intec Pharma from a strong-buy rating to a buy rating in a research report on Thursday, December 20th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Intec Pharma has a consensus rating of Buy and an average target price of $12.46.
Shares of NTEC opened at $8.94 on Monday. The company has a market capitalization of $294.78 million, a price-to-earnings ratio of -6.39 and a beta of 0.39. Intec Pharma has a 12 month low of $3.55 and a 12 month high of $9.25.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. PRW Wealth Management LLC purchased a new stake in Intec Pharma during the 4th quarter worth about $29,000. BlackRock Inc. purchased a new stake in Intec Pharma during the 4th quarter worth about $67,000. Essex Investment Management Co. LLC purchased a new stake in Intec Pharma during the 4th quarter worth about $2,972,000. Reilly Financial Advisors LLC purchased a new stake in shares of Intec Pharma in the 4th quarter valued at about $38,000. Finally, Prosight Management LP lifted its holdings in shares of Intec Pharma by 18.8% in the 3rd quarter. Prosight Management LP now owns 1,337,191 shares of the biotechnology company’s stock valued at $7,555,000 after purchasing an additional 212,038 shares during the last quarter. 40.30% of the stock is owned by institutional investors.
Intec Pharma Company Profile
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.
Featured Story: What are different types of coverage ratios?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.